Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,855 JPY | +1.72% | +4.47% | +8.44% |
Feb. 13 | LIM Advisors Partially Withdraws Shareholder Proposal | CI |
Feb. 09 | Torii Pharmaceuticals Opposes Shareholder Proposal | CI |
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The group usually releases upbeat results with huge surprise rates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.44% | 688M | - | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4551 Stock
- Ratings Torii Pharmaceutical Co., Ltd.